The US Patent and Trade Office (USPTO) has granted Mystic Pharmaceuticals US Patent No. 8,377,009, according to the company. The patent, titled “Intranasal Cartridge Devices,” covers technology for a delivery system based on Mystic’s unit dose delivery platforms for liquid or dry intranasal formulations of drugs and biologics.
Mystic President and CEO Timothy Sullivan commented, “The US market for nasal pharmaceuticals is projected to hit $4.25B by 2015 for a broad range of therapeutic drugs. Nasal vaccines will further expand this market opportunity for our technology. Our VersiDoser and VRx2 delivery solutions are designed to enhance the patient experience by making these products safer, easier and more convenient to use.”
The company’s delivery platform uses blister packaging of individual doses, and the devices come in disposable and reloadable versions.
Read the Mystic press release.
